Biotechnology
Commented by Fabian Lorenz on November 24th, 2022 | 12:40 CET
New year, rising prices? BASF, BioNTech and Manuka Resources - Shares in check
As the stock market year 2022 draws to a close, we look ahead to 2023. New year, rising prices? That is what many stock market players are hoping for. The chances are that we will see rising indices again with the end of interest rate hikes in the coming year. Today, we look at three companies likely to attract attention in 2023. At BioNTech, the research pipeline is full to bursting, and there are numerous study results to come. BASF is attractive due to its low valuation and high dividend yield. However, analysts warn of a write-off risk. Manuka Ressources convinces with a profitable core business, and an exciting project in the field of critical raw materials could lead to a revaluation.
Read
Commented by Stefan Feulner on November 22nd, 2022 | 13:42 CET
Favorable starting positions for Commerzbank, Desert Gold and BioNTech
The suspected downward pressure due to uncertainties in the economy and geopolitics has so far failed to materialize. Instead, the most important stock indices, such as DAX or Dow Jones, were able to leave their short-term downward trends and are sending signals for a further upward push. In addition to the stock market, the precious metals sector was also able to turn around. Here, in particular, entry opportunities beckon at a significantly reduced level with the chance of long-term, disproportionate price gains.
Read
Commented by Nico Popp on November 21st, 2022 | 12:11 CET
Biotech - Hotter than ever: Catalyst Pharmaceuticals, BioNxt Solutions, Bayer
Biotechs have been providing answers to humanity's most pressing questions for years. Innovative companies are applying advanced methods to make a medical difference. The example of BioNTech is just one success story among many. While companies in the pharmaceutical sector are finding it increasingly difficult to come up with real innovations, biotechs often put all their eggs in one basket - and win. We present two biotech hopefuls and take a look at Bayer.
Read
Commented by Stefan Feulner on November 21st, 2022 | 11:07 CET
Morphosys, Defence Therapeutics, Evotec - Stabilization after the sell-off
After the publication of the figures for the third quarter, many biotech companies were able to surprise positively. Due to the partly panic-like sell-off in this capital-intensive sector, there are attractive entry opportunities at a strongly discounted level, which should pay off with disproportionate price gains in the long term. The fact that promising companies are already trading below their cash levels shows that the panic is exaggerated. There are currently signs of a bottoming out, which could herald the next upward wave.
Read
Commented by Juliane Zielonka on November 18th, 2022 | 11:25 CET
Pfizer, Cardiol Therapeutics, Morphosys - Heart disease and cancer are on the rise!
No sooner is the Coronavirus in retreat than the damage caused by the pandemic measures comes to light. Young men, in particular, are affected by heart inflammation after two vaccinations with the Pfizer or Moderna vaccine. Reason enough for both companies to react to the research results of a small Canadian study with a new study that brought exactly that to light. On the other hand, the increase in myocarditis and pericarditis represents a great opportunity for Cardiol Therapeutics to successfully develop its active ingredient against pericarditis. So far, there is only one treatment available in the US that is purely inpatient, and it is in the five-digit USD range. With Cardiol's active ingredient, it may be possible to contain pericarditis more economically and effectively. Another consequence of the pandemic is an increase in cancer cases. Due to late diagnosis and a lack of access to health care, cancer is becoming a global health problem. Morphosys, still reeling this week from disappointing Alzheimer's trial results, however, has promising drugs in the pipeline.
Read
Commented by Juliane Zielonka on November 17th, 2022 | 13:48 CET
BioNxt Solutions, Pfizer, Bayer - Biotech and pharma stocks in focus
Pharma and biotech companies are still booming. However, large corporations like Pfizer and Bayer need help maintaining their market dominance with long-term studies and patent extensions. Pfizer, in particular, experienced the rush of speed in recent years thanks to the emergency approval of the Covid-19 vaccine. In hindsight, however, voices are growing louder about the potential long-term damage of this market cut. Multi-million dollar lawsuits may result. Positioning itself in the mental health niche, whose market size was USD 381.98 billion in 2020, is BioNxt Solutions. Their mission: to tackle depression, anxiety and PTSD with natural substances. A look at the data.
Read
Commented by Fabian Lorenz on November 17th, 2022 | 10:40 CET
Breaking news drives Nel ASA share: What are BioNTech and Kleos Space up to?
Growth stocks are currently celebrating a comeback. In particular, when there is also positive news from the company itself, as is the case with Nel ASA. The share of the hydrogen specialist increased by 40% within 4 weeks, and analysts see further potential for their "Top Pick". And then the Norwegians announced a cooperation with General Motors yesterday. BioNTech is also looking good from a chart and operational point of view. The cash box is full, allowing the Mainz-based company to increase production capacities. There is also something happening with space stocks. The valuation of Elon Musk's SpaceX is said to have risen by USD 25 billion in the latest round of financing, which should also improve the environment for Kleos Space. The specialist in space-based high-frequency reconnaissance is facing important weeks.
Read
Commented by Armin Schulz on November 16th, 2022 | 13:30 CET
BioNTech, Meta Materials, and Amazon - Industry leaders belong in the portfolio
In 2021, the stock market world was still in order - it had been going nowhere but up for years. That was the peak of the stock hype, and many top dogs in their industries were very expensive from a fundamental point of view. That has changed significantly this year. Due to the Ukraine conflict, rising interest rates and ever-higher inflation, many industry leaders had to make significant losses. Even a drop of 50% was not uncommon. Yet the long-term outlook is good. Now that the stock market is slowly regaining momentum, it is worth taking a look at three companies that are leaders in their field.
Read
Commented by André Will-Laudien on November 16th, 2022 | 11:27 CET
That hit home! Roche and Morphosys fail with Alzheimer's study, Bayer and Defence Therapeutics continue to rise strongly
It is common for biotech stocks to publish study results as well as figures several times a year. Since there are usually only expenses and few sales to report for these stocks fundamentally, analysts focus on the clinical successes in the way of a trial for the approval of new active substances. This can sometimes lead to erratic price movements. Roche and Morphosys suffered the same fate at the beginning of the week, with their share prices plummeting on the back of bad news. We take a look at a hot sector.
Read
Commented by Fabian Lorenz on November 9th, 2022 | 13:31 CET
BioNTech, Porsche and Pathfinder Ventures - Looking good
BioNTech's figures were convincing, and the chart looks good again. Porsche is doing well. Not all analysts see further price potential and the price targets diverge. However, a promotion to the DAX beckons. Pathfinder Ventures is also benefiting from surprisingly high demand. The winter camping resort offers are practically sold out. But first to BioNTech. After competitor Moderna had disappointed last week, the quarterly figures of the Mainz-based biotech Company were convincing. And due to the full pipeline, investors can expect a lively news flow in the coming year. Analysts are bullish.
Read